Last updated: 15 June 2019 at 9:18pm EST

Nishan Garabedian Christopher Net Worth




The estimated Net Worth of Nishan Garabedian Christopher is at least $3.79 million dollars as of 27 February 2015. Nishan Christopher owns over 800 units of Sarepta Therapeutics Inc stock worth over $3,794,181 and over the last 12 years Nishan sold SRPT stock worth over $0.

Nishan Christopher SRPT stock SEC Form 4 insiders trading

Nishan has made over 1 trades of the Sarepta Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Nishan bought 800 units of SRPT stock worth $9,456 on 27 February 2015.

The largest trade Nishan's ever made was buying 800 units of Sarepta Therapeutics Inc stock on 27 February 2015 worth over $9,456. On average, Nishan trades about 200 units every 0 days since 2012. As of 27 February 2015 Nishan still owns at least 29,552 units of Sarepta Therapeutics Inc stock.

You can see the complete history of Nishan Christopher stock trades at the bottom of the page.



What's Nishan Christopher's mailing address?

Nishan's mailing address filed with the SEC is 3450 MONTE VILLA PARKWAY, SUITE 101, , BOTHELL, WA, 98021.

Insiders trading at Sarepta Therapeutics Inc

Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry et M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.



What does Sarepta Therapeutics Inc do?

sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.



What does Sarepta Therapeutics Inc's logo look like?

Sarepta Therapeutics Inc logo

Complete history of Nishan Christopher stock trades at Sarepta Therapeutics Inc

Date
#
Société
Initié
Trans.
Transaction
Actions Prix par action Prix ​​total Actions après Source
27 Feb 2015 Nishan Garabedian Christopher
Président et PDG
Acheter 800 $11.82 $9,456
27 Feb 2015
29,552


Sarepta Therapeutics Inc executives and stock owners

Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include: